Developing new drugs to improve brain function in Alzheimer's disease
Development of Nav1.1 Enhancers to Treat Alzheimer's Disease
This study is testing a new type of medication that could help improve memory and brain function in people with early Alzheimer's by boosting a specific channel in the brain, which may reduce harmful proteins and inflammation.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cure Network Dolby Acceleration Partners LLC NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10701877 on NIH RePORTER |
What this research studies
This research focuses on creating a new class of drugs aimed at reversing early cognitive and physiological changes associated with Alzheimer's disease. The approach involves enhancing the activity of a specific sodium channel, Nav1.1, which has been shown to restore normal brain rhythms that are disrupted in Alzheimer's patients. By using small molecules to increase Nav1.1 activity, the research aims to reduce harmful protein accumulation and inflammation in the brain, potentially improving cognitive function. The research is based on promising results from animal models that suggest this method could effectively combat early Alzheimer's symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early-stage Alzheimer's disease who are experiencing cognitive decline.
Not a fit: Patients with advanced Alzheimer's disease or other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve cognitive function and quality of life for individuals with early Alzheimer's disease.
How similar studies have performed: Other research has shown promise in enhancing brain rhythms to improve cognitive function in Alzheimer's models, indicating that this approach may be viable.
Where this research is happening
San Francisco, United States
- Cure Network Dolby Acceleration Partners LLC — San Francisco, United States (Active)
Researchers
- Principal investigator: Pleiss, Michael — Cure Network Dolby Acceleration Partners LLC
- Study coordinator: Pleiss, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.